Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 13/20 | 0.39 |
| ▸ | MLYCD | O95822 | 4/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 6/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161492 | 0.85 | SLC6A2 (0.44) | HSD11B1CNR1MLYCD | |
| SCHEMBL161974 | 0.85 | HTT (0.42) | HSD11B1MAP4K4GCKMAP4K3MAP4K1 | |
| SCHEMBL28806672 | 0.84 | KIF11 (0.41) | CNR1MLYCDCNR2 | |
| SCHEMBL162160 | 0.77 | DGAT1 (0.42) | CNR1MLYCD | |
| SCHEMBL163197 | 0.77 | DGAT1 (0.52) | MLYCD | |
| SCHEMBL164736 | 0.77 | DGAT1 (0.52) | — | |
| SCHEMBL163324 | 0.76 | DGAT1 (0.52) | CNR1 | |
| SCHEMBL163981 | 0.73 | GPR119 (0.47) | — | |
| SCHEMBL159969 | 0.72 | MAP4K4 (0.38) | MLYCDMAP4K4GCKMAP4K3MAP4K1 | |
| SCHEMBL165783 | 0.70 | TRPV1 (0.37) | MLYCDMAP4K4GCKMAP4K3MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | HSD11B1 161/4885CNR1 946/4885MLYCD 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.